TL;DR
Although further investigation is needed to address safety and translational barriers, continued development of nanomedicine platforms holds significant potential to improve disease control and enhance the quality of life for patients with SLE.
This review provides a comprehensive overview of state-of-the-art lipid-based delivery systems specifically designed to overcome the unique pharmaceutical challenges associated with therapeutic glycoproteins, highlighting their design principles, formulation strategies, mechanisms of encapsulation and release, and ther...
This review critically summarizes recent developments in advanced nanocarriers for cancer therapy, emphasizing their design principles, therapeutic applications, clinical translation, and the key challenges influencing their future clinical adoption.
Current preclinical evidence supports nanomedicine as a central pillar of precision drug delivery, with future progress expected to focus on adaptive, multifunctional, and patient-specific platforms that align with the principles of personalized medicine.
In conclusion, while nanocarriers offer significant advancements in targeted cancer therapy, their successful clinical implementation depends on overcoming various scientific, technical, and regulatory challenges.
Breast cancer remains a major global health concern, highlighting the need for advanced drug delivery strategies that can improve therapeutic efficacy while minimizing systemic toxicity. Although several reviews have discussed polymeric nanocarriers for breast cancer therapy, many have primarily focused on specific p...
Conventional drug delivery approaches face challenges such as poor biodistribution, lack of target specificity, and systemic side effects, emphasizing the necessity for delivery systems that precisely deliver drugs to affected tissues while reducing exposure to nearby healthy organs. Targeted drug delivery systems (TDD...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
